BENGALURU (Reuters) - WCG Clinical Inc, a clinical trial solutions company backed by Singapore's sovereign wealth fund GIC, said on Tuesday it was aiming to raise up to US$765 million in its US initial public offering.
The IPO would value the company at $6.45 billion, at the top end of its targeted price range of between $15 and $17 per share, according to a regulatory filing. WCG, which also counts buyout firm Leonard Green & Partners LP among its investors, plans to sell 45 million shares as part of its IPO.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
